01
The Treatment Stack
Organized from upstream (the mast cell itself) to downstream (cardiovascular expression). Each layer addresses a different point in the cascade. Click to expand.
1
Mast Cell Stabilization
The upstream intervention — reduce degranulation and histamine load
›
H1 Antihistamines
cetirizine, loratadine, fexofenadine
Blocks histamine H1 receptors. Reduces itch, flushing, urticaria, neurological histamine load. Non-sedating preferred during day.
FDA Approved
H2 Antihistamines
famotidine, ranitidine
Blocks histamine H2 receptors — GI tract, cardiovascular. Often missed in HαT protocols. Run H1 and H2 together for full coverage.
FDA Approved
Cromolyn Sodium
Gastrocrom (oral)
Stabilizes mast cell membranes — prevents degranulation before it starts. Especially effective for GI mast cell burden. Works locally in gut.
FDA Approved
Ketotifen
compounded oral
H1 antagonist plus mast cell membrane stabilizer. Broader than cromolyn. Used in MCAS/HαT protocols. Compounded in US.
Emerging Use
Omalizumab
Xolair — anti-IgE
Documented clinical response in HαT specifically (Mendoza Alvarez et al. 2020). Most effective for anaphylaxis and urticaria in HαT. High cost barrier.
FDA Approved · HαT Evidence
Quercetin
supplement
Natural mast cell stabilizer — inhibits degranulation, reduces histamine and tryptase release. Low risk, accessible. Used as adjunct in MCAS protocols.
OTC Supplement
⚠ Zinc supplementation — commonly used in MCAS for histamine lowering — competes with copper absorption. If taking zinc, always measure copper simultaneously. High zinc may be inadvertently depleting copper and worsening mast cell reactivity via MITF derepression.
2
Brain & Neuroinflammation
Tryptase → PAR-2 → BBB → microglial activation → treatment-resistant depression, ADHD, anxiety, aggression
›
Low-Dose Naltrexone
LDN · 1.5–4.5mg nightly
Reduces microglial activation — the key neuroinflammatory driver in HαT. Blocks TLR4. Boosts endorphins via rebound. Documented response in MCAS + depression + POTS simultaneously. Start low, titrate slowly.
Emerging · Off-label · Strong Signal
Dextromethorphan / Bupropion
Auvelity
NMDA antagonist + sigma-1 agonist + dopamine/norepinephrine reuptake inhibition. Addresses glutamate excitotoxicity from chronic neuroinflammation. FDA approved MDD 2022, Alzheimer's agitation 2026. Direct mechanism match for HαT neuropsychiatric phenotype.
FDA Approved · On-Mechanism
Guanfacine
Intuniv, Tenex
Alpha-2 adrenergic agonist. Reduces sympathetic tone and prefrontal hyperarousal. Directly addresses hyperadrenergic component. Superior to stimulants in HαT-driven ADHD — stimulants treat downstream dopamine; guanfacine addresses the hyperadrenergic nervous system directly.
FDA Approved · Clinical Evidence in HαT ADHD
Low-Dose Doxepin
Silenor · 3–6mg
H1/H2 antagonist — addresses histamine-driven wakefulness blocking slow-wave sleep. Restores glymphatic clearance by enabling deep sleep. FDA approved for insomnia. Do not use standard antidepressant doses — low dose only for sleep architecture.
FDA Approved for Insomnia
⚠ Standard SSRIs do not address the mechanism in HαT. The serotonin deficit is downstream of neuroinflammation — treating the smoke, not the fire. SSRIs are not wrong, but incomplete. LDN addresses neuroinflammation upstream. Auvelity addresses glutamate excitotoxicity and dopamine/norepinephrine simultaneously.
3
Autonomic Support & POTS
Downstream cardiovascular expression of neuroinflammation + vascular permeability + DBH impairment
›
Ivabradine
Corlanor
Reduces heart rate by blocking If channels in the SA node — without beta blockade. Better tolerated in mast cell patients than beta blockers. Directly addresses tachycardia in POTS without suppressing the sympathetic system needed for vascular tone.
FDA Approved
Pyridostigmine
Mestinon
Acetylcholinesterase inhibitor — strengthens vagal (parasympathetic) tone directly. Particularly relevant in HαT given copper-deficient DMV neuron impairment. Addresses the vagal brake failure from both the neuroinflammatory and copper-DBH sides simultaneously.
Off-label for POTS · Emerging Evidence
Midodrine
ProAmatine
Alpha-1 agonist — vasoconstriction. Addresses the vascular permeability/hypovolemia component from tryptase-mediated PAR-2 activation. Salt loading is not wrong, but incomplete — the vessels are leaky. Midodrine helps retain volume.
FDA Approved for OH
Fludrocortisone
Florinef
Mineralocorticoid — promotes sodium and water retention, expanding plasma volume. Standard POTS protocol. In HαT, addresses the hypovolemia but not the tryptase-driven vascular permeability causing it. Useful adjunct, not standalone.
FDA Approved
Note on salt loading: appropriate but incomplete in HαT. The problem is not insufficient salt intake but insufficient retention — vessels are leaky from PAR-2 activation. Mast cell stabilization is the upstream intervention that addresses the source of the leak.
4
The Copper Axis
LOX · MITF · DAO · DBH — four copper-dependent mechanisms compounding HαT severity
›
Copper Bisglycinate
preferred form
Best-absorbed oral copper form. Supports LOX (collagen crosslinking), MITF brake on tryptase expression, DAO (histamine clearance), and DBH (norepinephrine synthesis). Dose and form should be guided by lab results — do not supplement blind.
Novel in HαT · Lab-Guided
DAO Enzyme Supplement
diamine oxidase oral
Exogenous DAO to compensate for copper-insufficient endogenous DAO. Taken before histamine-containing meals. Addresses the third copper mechanism directly. Available OTC in some countries, prescription in others.
OTC / Supplement
⚠ Causal direction is critical: copper deficiency worsens HαT, but HαT does not predictably deplete copper. Always measure before supplementing. Serum copper alone is insufficient — inflammation raises ceruloplasmin and can mask deficiency. Order: serum copper + ceruloplasmin + RBC copper + serum zinc + DAO activity. RBC copper is the most sensitive functional marker.
5
The Pipeline — What Doesn't Exist Yet
PAR-2 antagonists, tryptase inhibitors, and the LigandForge target
›
PAR-2 Antagonist
does not exist — highest priority
Would interrupt the cascade upstream of MMP activation, BBB disruption, and autonomic dysregulation. The first precision medicine intervention for HαT that addresses the root rather than downstream expressions. LigandForge (Watson 2026) is the computational tool that could design one against the α/β heterotetramer.
Pipeline · Unfunded
α/β Heterotetramer Inhibitor
does not exist
Current tryptase inhibitors (nafamostat Ki 95.3 pM) were designed against beta-tryptase homotetramers. The HαT active species is the alpha/beta heterotetramer — unique geometry at the D216 anchor. Whether existing inhibitors work against this target has never been tested.
Pipeline · Unstudied
Lactoferrin
natural tetramer disruptor
Ki 24 nM — disassembles active tryptase tetramers by displacing heparin. Inhibits mast cell histamine release up to 50%. Available in supplement form and colostrum. Whether it disrupts α/β heterotetramers equally — unstudied. Immediately actionable low-risk research question.
Natural · Emerging Research
The most important gap in HαT therapeutics is not a knowledge gap — it is a research funding gap. The mechanism is known. The target is defined. The computational tools to design an inhibitor exist. The study has not been done.
You are not broken.
You are a Sentinel running on depleted fuel.
You are a Sentinel running on depleted fuel.
The Advantage
Extra TPSAB1 copies meant faster immune response to parasites and pathogens. A nervous system pre-wired for high-alert vigilance. Your ancestors were the ones who smelled the smoke first. The gene is not a mistake.
The Mismatch
That high-performance alert system requires adequate mineral fuel — especially copper — to keep the engine from overheating. Modern soil depletion, processed food, and chronic environmental triggers mean the Sentinel is firing constantly on an empty tank.
The Intervention
Stabilize the mast cell. Calm the neuroinflammation. Support the autonomic system. Check the fuel gauge — copper, ceruloplasmin, zinc, DAO. The goal is not suppression. It is restoration of a system that was never broken — just overloaded.
02
The Labs to Order
In priority order. All standard commercial labs. Most can be drawn in a single visit.
Basal Serum Tryptase
The HαT screening test. Must be drawn at baseline — not during reaction.
Result ≥8.0 ng/mL warrants clinical consideration of HαT. The standard 11.4 ng/mL cutoff misses carriers. Alheraky 2024 recommends ≥9.2 ng/mL as the clinical flag. Confirm with ddPCR TPSAB1 copy number if available.
Serum Copper + Ceruloplasmin
The copper axis screen. Always order together — neither alone is sufficient.
Low ceruloplasmin with low copper = true deficiency. Normal serum copper does not rule out functional deficiency in active inflammation — ceruloplasmin is an acute phase reactant and rises with mast cell disease.
⚠ Serum copper alone will miss functional deficiency in actively inflamed HαT carriers.
RBC Copper / SOD Activity
The most sensitive functional copper marker — reflects intracellular availability.
SOD1 is copper-dependent. RBC SOD activity declines before serum copper falls below normal reference range. This is the test most likely to detect functional copper insufficiency masked by ceruloplasmin elevation from inflammation.
Serum Zinc
Essential for interpreting copper — zinc and copper compete for absorption.
High zinc from supplementation (common in MCAS self-management) is a documented cause of secondary copper deficiency. If zinc is elevated alongside low copper, iatrogenic depletion from supplementation is the likely cause — and is correctable.
DAO Activity
Measures histamine clearance capacity — the third copper mechanism.
Low DAO + elevated BST + elevated mast cell histamine = histamine accumulating from both excess production and impaired clearance simultaneously. Copper repletion should improve DAO activity if copper is the limiting factor.
Full Iron Panel + Ferritin
Iron and copper are co-dependent through ceruloplasmin-ferroxidase activity.
Ceruloplasmin impairment from copper insufficiency creates functional iron deficiency even when total iron stores appear adequate. Ferritin can be misleadingly normal or elevated as an acute phase reactant. TSAT and serum iron together give the functional picture.
ddPCR TPSAB1 Copy Number
Confirms HαT genotype and establishes copy number dose.
Required for formal HαT diagnosis. Not widely available outside academic centers. Copy number correlates with BST level (Pearson r=0.868, Hernández-Hernández 2021). Referral to allergy/immunology for access. Currently available at NIH and select academic labs.
Heart Rate Variability (HRV)
Functional measure of vagal tone — the parasympathetic brake.
Low HRV in HαT reflects both neuroinflammatory vagal compromise and potential copper-DBH impairment of norepinephrine synthesis. Baseline HRV before and after copper repletion or pyridostigmine would directly test the DBH hypothesis from Paper 2.
For the Clinician
What to Know Before the Appointment
Your patient may not have the language for this yet. They know they have POTS, ADHD, hypermobility, treatment-resistant depression, and a family history of early cardiac events. They don't know these are one cascade. Here is what the literature supports — and what to order.
1
Draw a basal serum tryptase. Not during a reaction — at baseline. Interpret ≥8.0 ng/mL as warranting HαT consideration, not the standard 11.4 ng/mL cutoff. The current reference range was derived from cohorts that did not account for HαT prevalence.
2
Order the copper panel alongside BST. Serum copper + ceruloplasmin + RBC copper + serum zinc. Serum copper alone is insufficient in an inflamed patient — ceruloplasmin rises with mast cell disease and can mask deficiency. RBC copper is the functional marker that doesn't lie.
3
Ask about zinc supplementation. MCAS patients commonly self-administer zinc for histamine lowering. High zinc competitively depletes copper via shared intestinal transporters. Iatrogenic copper deficiency in this population is underrecognized and directly worsens mast cell reactivity through MITF derepression.
4
Consider LDN before another SSRI. If treatment-resistant depression with neuroinflammatory features — brain fog, sensory overload, hypervigilance — the mechanism is PAR-2 → astrocytic IL-6/TNF-α → serotonin transporter downregulation. LDN addresses microglial activation upstream. Auvelity addresses NMDA excitotoxicity and dopamine/norepinephrine simultaneously. SSRIs treat the smoke.
5
For unexplained visual symptoms — check copper urgently. Optic neuropathy from copper deficiency is progressive and may be irreversible if not caught early. HαT carriers with tryptase-driven PAR-2 neuroinflammation plus copper-insufficient demyelination are hitting the optic nerve from two directions simultaneously.
This guide is a patient and clinician education resource based on published peer-reviewed literature and the hypothesis papers produced by Tryptase Place (The Generational Load v10; The Copper Axis in HαT v1). It is not a substitute for individualized medical advice. All treatment decisions should be made in consultation with qualified clinicians familiar with mast cell disorders and autonomic dysfunction. Citations available at tryptaseplace.org.